Morgan Stanley lowered shares of Sanofi (NYSE:SNY) from an overweight rating to an underweight rating in a research report released on Friday, Marketbeat reports.
SNY has been the topic of several other reports. Argus reiterated a buy rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. upgraded Sanofi from a reduce rating to a hold rating in a research note on Wednesday, August 30th. BidaskClub upgraded Sanofi from a sell rating to a hold rating in a research note on Saturday, August 5th. Barclays upgraded Sanofi from an underweight rating to an equal weight rating in a research note on Wednesday, November 15th. Finally, J P Morgan Chase & Co reiterated a neutral rating on shares of Sanofi in a research note on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $53.50.
Sanofi (NYSE SNY) traded down $1.02 during trading on Friday, hitting $44.62. The stock had a trading volume of 1,767,900 shares, compared to its average volume of 1,504,120. Sanofi has a twelve month low of $38.45 and a twelve month high of $50.65. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $112,509.69, a price-to-earnings ratio of 14.08, a PEG ratio of 2.46 and a beta of 0.86.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.